A Multicenter, Post-marketing Surveillance Study to Monitor the Safety of Novartis Vaccine MF59-adjuvanted Influenza Subunit Vaccine FLUAD® and Sandoz Korea Vaccine MF59-adjuvanted Influenza Subunit Vaccine VANTAFLU® Administered According to the Prescribing Information in Korean Subjects Aged 65 Years or Older at the Time of Vaccination.

Trial Profile

A Multicenter, Post-marketing Surveillance Study to Monitor the Safety of Novartis Vaccine MF59-adjuvanted Influenza Subunit Vaccine FLUAD® and Sandoz Korea Vaccine MF59-adjuvanted Influenza Subunit Vaccine VANTAFLU® Administered According to the Prescribing Information in Korean Subjects Aged 65 Years or Older at the Time of Vaccination.

Completed
Phase of Trial: Phase IV

Latest Information Update: 14 Oct 2015

At a glance

  • Drugs Influenza virus vaccine (Primary) ; MF 59
  • Indications Influenza virus infections
  • Focus Adverse reactions
  • Sponsors Novartis; Novartis Vaccines
  • Most Recent Events

    • 01 Dec 2014 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
    • 25 Jun 2014 As per NCT study title, trial design, number of treatment arms got changed.
    • 18 Nov 2013 Status changed from active, no longer recruiting to recruiting as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top